Stefan W. Henning
Plus aucun poste en cours
Profil
Stefan W.
Henning has been Senior Director Research and Technology for Avontec GmbH since September 2005.
Prior to joining Avontec, he was Research Director of Xerion Pharmaceuticals AG.
Dr. Henning received a PhD in Biochemistry and Immunology from the Eberhard Karls Universität Tübingen.
Anciens postes connus de Stefan W. Henning
| Sociétés | Poste | Fin |
|---|---|---|
Xerion Pharmaceuticals AG
 Xerion Pharmaceuticals AG Pharmaceuticals: MajorHealth Technology Xerion Pharmaceuticals GmbH develops antibodies and therapeutic targets. It uniquely focuses on proteins, using proprietary technologies to selectively block their function in diseased cells thereby mimicking the activity of a drug. The company is headquartered in Munich, Germany. | Directeur Technique/Scientifique/R&D | - |
Avontec GmbH
 Avontec GmbH Pharmaceuticals: MajorHealth Technology Avontec is a Phase 2 biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for inflammatory disease. Its clinical development programs include product candidates for multiple potential inflammatory indications. The two most advanced, AVT-01 in asthma and AVT-02 in psoriasis, have successfully advanced into Phase 2a clinical trials that the firm expects to be completed until the first half of 2008. In addition, there are several candidates in the pipeline based on Avontec's core decoy technology. Avontec operates based on a lean business model with a seasoned management team experienced in clinical development. | Directeur Technique/Scientifique/R&D | - |
Formation de Stefan W. Henning
| Eberhard Karls Universität Tübingen | Doctorate Degree |
Expériences
Fonctions occupées
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Avontec GmbH
Avontec GmbH Pharmaceuticals: MajorHealth Technology Avontec is a Phase 2 biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for inflammatory disease. Its clinical development programs include product candidates for multiple potential inflammatory indications. The two most advanced, AVT-01 in asthma and AVT-02 in psoriasis, have successfully advanced into Phase 2a clinical trials that the firm expects to be completed until the first half of 2008. In addition, there are several candidates in the pipeline based on Avontec's core decoy technology. Avontec operates based on a lean business model with a seasoned management team experienced in clinical development. | Health Technology |
Xerion Pharmaceuticals AG
Xerion Pharmaceuticals AG Pharmaceuticals: MajorHealth Technology Xerion Pharmaceuticals GmbH develops antibodies and therapeutic targets. It uniquely focuses on proteins, using proprietary technologies to selectively block their function in diseased cells thereby mimicking the activity of a drug. The company is headquartered in Munich, Germany. | Health Technology |
